Inconvenient truth: Cancer biomarker development by using proteomics

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 5, 2014, Pages 861-865

  Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Biomarker; Cancer; Proteomics

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; EARLY DIAGNOSIS; GENOME; HUMAN; NEOPLASM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW;

BIOMARKER; CANCER; PROTEOMICS;

ANIMALS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898599851     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2013.07.009     Document Type: Review

References (55)

1. J.A. Ludwig, and J.N. Weinstein Biomarkers in cancer staging, prognosis and treatment selection Nat. Rev. Cancer 5 2005 845 856 (Pubitemid 41746029)
2. JAPAN CANCER STATISTICS IN Foundation for Promotion of Cancer Research, 2012 2012
3. R.C. Marcove, V. Mike, J.V. Hajek, A.G. Levin, and R.V. Hutter Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases J. Bone Joint Surg. Am. 52 1970 411 423
4. A.J. Provisor, L.J. Ettinger, J.B. Nachman, M.D. Krailo, J.T. Makley, E.J. Yunis, A.G. Huvos, D.L. Betcher, E.S. Baum, C.T. Kisker, and J.S. Miser Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group J. Clin. Oncol. 15 1997 76 84 (Pubitemid 27020560)
5. T. Fukui, S. Mori, S. Hatooka, M. Shinoda, and T. Mitsudomi Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers J. Thorac. Cardiovasc. Surg. 136 2008 1343 1348
6. B.M. Stiles, E.L. Servais, P.C. Lee, J.L. Port, S. Paul, and N.K. Altorki Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging J. Thorac. Cardiovasc. Surg. 137 2009 13 19
7. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139 (Pubitemid 38637993)
8. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
9. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, and H. Varmus EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U. S. A. 101 2004 13306 13311 (Pubitemid 39209661)
10. B.P. Rubin, M.C. Heinrich, and C.L. Corless Gastrointestinal stromal tumour Lancet 369 2007 1731 1741 (Pubitemid 46778870)
11. H. Joensuu, P.J. Roberts, M. Sarlomo-Rikala, L.C. Andersson, P. Tervahartiala, D. Tuveson, S. Silberman, R. Capdeville, S. Dimitrijevic, B. Druker, and G.D. Demetri Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N. Engl. J. Med. 344 2001 1052 1056 (Pubitemid 32267975)
12. R. Dagher, M. Cohen, G. Williams, M. Rothmann, J. Gobburu, G. Robbie, A. Rahman, G. Chen, A. Staten, D. Griebel, and R. Pazdur Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors Clin. Cancer Res. 8 2002 3034 3038 (Pubitemid 35155011)
13. H. Joensuu, M. Eriksson, K. Sundby Hall, J.T. Hartmann, D. Pink, J. Schutte, G. Ramadori, P. Hohenberger, J. Duyster, S.E. Al-Batran, M. Schlemmer, S. Bauer, E. Wardelmann, M. Sarlomo-Rikala, B. Nilsson, H. Sihto, O.R. Monge, P. Bono, R. Kallio, A. Vehtari, M. Leinonen, T. Alvegard, and P. Reichardt One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JAMA 307 2012 1265 1272
14. H. Joensuu, A. Vehtari, J. Riihimaki, T. Nishida, S.E. Steigen, P. Brabec, L. Plank, B. Nilsson, C. Cirilli, C. Braconi, A. Bordoni, M.K. Magnusson, Z. Linke, J. Sufliarsky, M. Federico, J.G. Jonasson, A.P. Dei Tos, and P. Rutkowski Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts Lancet Oncol. 13 2012 265 274
15. S. Hanash, and A. Taguchi The grand challenge to decipher the cancer proteome Nat. Rev. Cancer 10 2010 652 660
16. S.M. Hanash, S.J. Pitteri, and V.M. Faca Mining the plasma proteome for cancer biomarkers Nature 452 2008 571 579 (Pubitemid 351483371)
17. J.N. Adkins, S.M. Varnum, K.J. Auberry, R.J. Moore, N.H. Angell, R.D. Smith, D.L. Springer, and J.G. Pounds Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry Mol. Cell. Proteomics 1 2002 947 955
18. L.A. Echan, H.Y. Tang, N. Ali-Khan, K. Lee, and D.W. Speicher Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma Proteomics 5 2005 3292 3303 (Pubitemid 41192036)
19. L. Anderson, and C.L. Hunter Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins Mol. Cell. Proteomics 5 2006 573 588
20. D.K. Ornstein, J.W. Gillespie, C.P. Paweletz, P.H. Duray, J. Herring, C.D. Vocke, S.L. Topalian, D.G. Bostwick, W.M. Linehan, E.F. Petricoin III, and M.R. Emmert-Buck Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines Electrophoresis 21 2000 2235 2242 (Pubitemid 30435823)
21. B.L. Hood, M.M. Darfler, T.G. Guiel, B. Furusato, D.A. Lucas, B.R. Ringeisen, I.A. Sesterhenn, T.P. Conrads, T.D. Veenstra, and D.B. Krizman Proteomic analysis of formalin-fixed prostate cancer tissue Mol. Cell. Proteomics 4 2005 1741 1753 (Pubitemid 41749267)
22. B.B. Haab Advances in protein microarray technology for protein expression and interaction profiling Curr. Opin. Drug Discov. Devel. 4 2001 116 123 (Pubitemid 32118467)
23. M.V. Yezhelyev, X. Gao, Y. Xing, A. Al-Hajj, S. Nie, and R.M. O'Regan Emerging use of nanoparticles in diagnosis and treatment of breast cancer Lancet Oncol. 7 2006 657 667 (Pubitemid 44143778)
24. K. Hede $104 million proteomics initiative gets green light J. Natl. Cancer Inst. 97 2005 1324 1325 (Pubitemid 41487795)
25. E. Check Proteomics and cancer: running before we can walk? Nature 429 2004 496 497 (Pubitemid 38737636)
26. S.M. Hanash Why have protein biomarkers not reached the clinic? Genome Med. 3 2011 66
27. G. Poste Bring on the biomarkers Nature 469 2011 156 157
28. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, F.L. Baehner, M.G. Walker, D. Watson, T. Park, W. Hiller, E.R. Fisher, D.L. Wickerham, J. Bryant, and N. Wolmark A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N. Engl. J. Med. 351 2004 2817 2826 (Pubitemid 40051905)
29. L.J. van't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, H.L. Peterse, K. van der Kooy, M.J. Marton, A.T. Witteveen, G.J. Schreiber, R.M. Kerkhoven, C. Roberts, P.S. Linsley, R. Bernards, and S.H. Friend Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536 (Pubitemid 34130608)
30. A.M. Glas, A. Floore, L.J. Delahaye, A.T. Witteveen, R.C. Pover, N. Bakx, J.S. Lahti-Domenici, T.J. Bruinsma, M.O. Warmoes, R. Bernards, L.F. Wessels, and L.J. Van't Veer Converting a breast cancer microarray signature into a high-throughput diagnostic test BMC Genomics 7 2006 278
31. N.L. Anderson, and N.G. Anderson The human plasma proteome: history, character, and diagnostic prospects Mol. Cell. Proteomics 1 2002 845 867
32. S.S. Hori, and S.S. Gambhir Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations Sci. Transl. Med. 3 2011 109 116
33. Q. Zhang, V. Faca, and S. Hanash Mining the plasma proteome for disease applications across seven logs of protein abundance J. Proteome Res. 10 2011 46 50
34. D.F. Ransohoff Rules of evidence for cancer molecular-marker discovery and validation Nat. Rev. Cancer 4 2004 309 314 (Pubitemid 38525286)
35. D.F. Ransohoff Bias as a threat to the validity of cancer molecular-marker research Nat. Rev. Cancer 5 2005 142 149 (Pubitemid 40215862)
36. E.T. Fung A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance Clin. Chem. 56 2010 327 329
37. E.F. Petricoin, and L.A. Liotta SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer Curr. Opin. Biotechnol. 15 2004 24 30 (Pubitemid 38224245)
38. M.P. Washburn, D. Wolters, and J.R. Yates III Large-scale analysis of the yeast proteome by multidimensional protein identification technology Nat. Biotechnol. 19 2001 242 247 (Pubitemid 32220565)
39. M. Kowalewska, R. Nowak, and M. Chechlinska Implications of cancer-associated systemic inflammation for biomarker studies Biochim. Biophys. Acta 1806 2010 163 171
40. M. Chechlinska, M. Kowalewska, and R. Nowak Systemic inflammation as a confounding factor in cancer biomarker discovery and validation Nat. Rev. Cancer 10 2010 2 3
41. H. Lu, W. Ouyang, and C. Huang Inflammation, a key event in cancer development Mol. Cancer Res. 4 2006 221 233
42. W.W. Pang, P.S. Abdul-Rahman, W.I. Wan-Ibrahim, and O.H. Hashim Can the acute-phase reactant proteins be used as cancer biomarkers? Int. J. Biol. Markers 25 2010 1 11
43. D.J. Brennan, D.P. O'Connor, E. Rexhepaj, F. Ponten, and W.M. Gallagher Antibody-based proteomics: fast-tracking molecular diagnostics in oncology Nat. Rev. Cancer 10 2010 605 617
44. M. Noguchi, A. Morikawa, M. Kawasaki, Y. Matsuno, T. Yamada, S. Hirohashi, H. Kondo, and Y. Shimosato Small adenocarcinoma of the lung. Histologic characteristics and prognosis Cancer 75 1995 2844 2852
45. L. Sobin, M. Gospodarowicz, and C. Wittekind 7th TNM Classification of Malignant Tumours 7th ed. 2009 Wiley-Blackwell
46. T. Kondo, M. Seike, Y. Mori, K. Fujii, T. Yamada, and S. Hirohashi Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool Proteomics 3 2003 1758 1766 (Pubitemid 37129823)
47. L.F. Waanders, K. Chwalek, M. Monetti, C. Kumar, E. Lammert, and M. Mann Quantitative proteomic analysis of single pancreatic islets Proc. Natl. Acad. Sci. U. S. A. 106 2009 18902 18907
48. H. Hatakeyama, T. Kondo, K. Fujii, Y. Nakanishi, H. Kato, S. Fukuda, and S. Hirohashi Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer Proteomics 6 2006 6300 6316 (Pubitemid 44935516)
49. T. Orimo, H. Ojima, N. Hiraoka, S. Saito, T. Kosuge, T. Kakisaka, H. Yokoo, K. Nakanishi, T. Kamiyama, S. Todo, S. Hirohashi, and T. Kondo Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma Hepatology 48 2008 1851 1863
50. Y. Sugihara, H. Taniguchi, R. Kushima, H. Tsuda, D. Kubota, H. Ichikawa, S. Fujita, and T. Kondo Laser microdissection and two-dimensional difference gel electrophoresis reveal proteomic intra-tumor heterogeneity in colorectal cancer J. Proteomics 78 2013 134 147
51. T. Kondo, and S. Hirohashi Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics Nat. Protoc. 1 2007 2940 2956
52. J.P. Shapiro, S. Biswas, A.S. Merchant, A. Satoskar, C. Taslim, S. Lin, B.H. Rovin, C.K. Sen, S. Roy, and M.A. Freitas A quantitative proteomic workflow for characterization of frozen clinical biopsies: laser capture microdissection coupled with label-free mass spectrometry J. Proteomics 77 2012 433 440
53. R.B. Braakman, M.M. Tilanus-Linthorst, N.Q. Liu, C. Stingl, L.J. Dekker, T.M. Luider, J.W. Martens, J.A. Foekens, and A. Umar Optimized nLC-MS workflow for laser capture microdissected breast cancer tissue J. Proteomics 75 2012 2844 2854
54. D.J. Johann, J. Rodriguez-Canales, S. Mukherjee, D.A. Prieto, J.C. Hanson, M. Emmert-Buck, and J. Blonder Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry J. Proteome Res. 8 2009 2310 2318
55. B.J. Xu, J. Li, R.D. Beauchamp, Y. Shyr, M. Li, M.K. Washington, T.J. Yeatman, R.H. Whitehead, R.J. Coffey, and R.M. Caprioli Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS Mol. Cell. Proteomics 8 2009 936 945